EA021588B1 - Бетаиновые соли ацетилсалициловой кислоты - Google Patents
Бетаиновые соли ацетилсалициловой кислоты Download PDFInfo
- Publication number
- EA021588B1 EA021588B1 EA201200038A EA201200038A EA021588B1 EA 021588 B1 EA021588 B1 EA 021588B1 EA 201200038 A EA201200038 A EA 201200038A EA 201200038 A EA201200038 A EA 201200038A EA 021588 B1 EA021588 B1 EA 021588B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- relative
- platelet aggregation
- treatment
- acetylsalicylic acid
- prevention
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical class CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 27
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical class C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 title abstract description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 229960002937 meldonium Drugs 0.000 claims abstract description 21
- PVBQYTCFVWZSJK-UHFFFAOYSA-N meldonium Chemical compound C[N+](C)(C)NCCC([O-])=O PVBQYTCFVWZSJK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000007170 pathology Effects 0.000 claims abstract description 16
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims abstract description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 3
- 238000011282 treatment Methods 0.000 claims description 37
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 31
- 208000007536 Thrombosis Diseases 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- 230000004054 inflammatory process Effects 0.000 claims description 22
- 230000002265 prevention Effects 0.000 claims description 22
- 229960003512 nicotinic acid Drugs 0.000 claims description 20
- 235000001968 nicotinic acid Nutrition 0.000 claims description 20
- 239000011664 nicotinic acid Substances 0.000 claims description 20
- 201000001320 Atherosclerosis Diseases 0.000 claims description 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 229940126534 drug product Drugs 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 230000036407 pain Effects 0.000 claims description 8
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 238000002441 X-ray diffraction Methods 0.000 claims description 6
- 230000003143 atherosclerotic effect Effects 0.000 claims description 6
- 229960003009 clopidogrel Drugs 0.000 claims description 6
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 230000000552 rheumatic effect Effects 0.000 claims description 6
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 5
- 229960002768 dipyridamole Drugs 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims 6
- 208000001435 Thromboembolism Diseases 0.000 claims 6
- 208000006011 Stroke Diseases 0.000 claims 5
- 230000000302 ischemic effect Effects 0.000 claims 5
- 239000000654 additive Substances 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 210000004351 coronary vessel Anatomy 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 16
- 229940127218 antiplatelet drug Drugs 0.000 abstract description 10
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 85
- 239000000126 substance Substances 0.000 description 75
- 230000000694 effects Effects 0.000 description 69
- 241001465754 Metazoa Species 0.000 description 63
- 241000700159 Rattus Species 0.000 description 57
- 239000007924 injection Substances 0.000 description 37
- 238000002347 injection Methods 0.000 description 37
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 230000009471 action Effects 0.000 description 23
- 230000001698 pyrogenic effect Effects 0.000 description 22
- 206010030113 Oedema Diseases 0.000 description 21
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 208000034158 bleeding Diseases 0.000 description 20
- 230000000740 bleeding effect Effects 0.000 description 20
- 230000000202 analgesic effect Effects 0.000 description 18
- 230000007423 decrease Effects 0.000 description 18
- 230000002776 aggregation Effects 0.000 description 17
- 238000004220 aggregation Methods 0.000 description 17
- 229940114079 arachidonic acid Drugs 0.000 description 17
- 235000021342 arachidonic acid Nutrition 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 230000017531 blood circulation Effects 0.000 description 16
- 239000000679 carrageenan Substances 0.000 description 16
- 235000010418 carrageenan Nutrition 0.000 description 16
- 229920001525 carrageenan Polymers 0.000 description 16
- 229940113118 carrageenan Drugs 0.000 description 16
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 206010003246 arthritis Diseases 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 230000001754 anti-pyretic effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 229940068372 acetyl salicylate Drugs 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 208000035150 Hypercholesterolemia Diseases 0.000 description 8
- 231100000403 acute toxicity Toxicity 0.000 description 8
- 230000007059 acute toxicity Effects 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- XFDUHJPVQKIXHO-UHFFFAOYSA-N 3-aminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-N 0.000 description 7
- 241000989747 Maba Species 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000013021 overheating Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000003356 anti-rheumatic effect Effects 0.000 description 6
- 239000002221 antipyretic Substances 0.000 description 6
- 210000000544 articulatio talocruralis Anatomy 0.000 description 6
- 238000003359 percent control normalization Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 206010003178 Arterial thrombosis Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical compound C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 description 5
- 229950008292 laropiprant Drugs 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000007625 Hirudins Human genes 0.000 description 4
- 108010007267 Hirudins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000002744 anti-aggregatory effect Effects 0.000 description 4
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000001715 carotid artery Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 229940006607 hirudin Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- CPYFMBLTTJVZCP-UHFFFAOYSA-N CCC(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O Chemical compound CCC(O)=O.CC(=O)OC1=CC=CC=C1C(O)=O CPYFMBLTTJVZCP-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010007688 Carotid artery thrombosis Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- -1 Gamma-butyrobetaine dihydrate Chemical class 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- IHWNOPAHRHEFIE-GFCCVEGCSA-N (3r)-3-(2-acetyloxybenzoyl)oxy-4-(trimethylazaniumyl)butanoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHWNOPAHRHEFIE-GFCCVEGCSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000002322 anti-exudative effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009529 body temperature measurement Methods 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 231100000334 hepatotoxic Toxicity 0.000 description 2
- 230000003082 hepatotoxic effect Effects 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- HJTDTENJBWSGMT-UHFFFAOYSA-N C(C)(=O)OC=1C(C(=O)O)=CC=CC1.C(CCC)(=O)O Chemical compound C(C)(=O)OC=1C(C(=O)O)=CC=CC1.C(CCC)(=O)O HJTDTENJBWSGMT-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001442654 Percnon planissimum Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 101100290389 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ceg1 gene Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000678 effect on lipid Effects 0.000 description 1
- 230000002866 effect on thrombosis Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940030627 lipid modifying agent Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- PPQFUDZMTNGHBJ-UHFFFAOYSA-N propanoic acid;dihydrate Chemical compound O.O.CCC(O)=O PPQFUDZMTNGHBJ-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-M prostaglandin I2(1-) Chemical compound O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-M 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 102220082846 rs373113507 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/40—Hydrazines having nitrogen atoms of hydrazine groups being quaternised
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/14—Acetic acid esters of monohydroxylic compounds
- C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
- C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LVP-09-117A LV14273B (lv) | 2009-06-25 | 2009-06-25 | Jauni acetilsalicilskābes sāļi |
| PCT/LV2010/000007 WO2010151095A1 (en) | 2009-06-25 | 2010-06-21 | Novel acetylsalicylic acid salts |
| LVP-10-95A LV14468B (lv) | 2010-06-21 | 2010-06-21 | Pretiekaisuma līdzeklis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201200038A1 EA201200038A1 (ru) | 2012-10-30 |
| EA021588B1 true EA021588B1 (ru) | 2015-07-30 |
Family
ID=42562394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200038A EA021588B1 (ru) | 2009-06-25 | 2010-06-21 | Бетаиновые соли ацетилсалициловой кислоты |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8889902B2 (enExample) |
| EP (1) | EP2445861B1 (enExample) |
| JP (1) | JP5706409B2 (enExample) |
| KR (1) | KR20120050437A (enExample) |
| CN (1) | CN102803199B (enExample) |
| BR (1) | BRPI1009600A2 (enExample) |
| CA (1) | CA2766048A1 (enExample) |
| EA (1) | EA021588B1 (enExample) |
| GE (1) | GEP20146015B (enExample) |
| IL (1) | IL217036A (enExample) |
| NZ (1) | NZ597510A (enExample) |
| WO (1) | WO2010151095A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140088125A1 (en) * | 2011-04-27 | 2014-03-27 | Jsc Grindeks | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
| CN103547562A (zh) * | 2011-04-27 | 2014-01-29 | 格林代克斯联合股份公司 | 4-[(卤代烷基)(二甲基)铵基]丁酸盐及其在治疗心血管疾病中的用途 |
| LV14606B (lv) | 2011-05-17 | 2013-01-20 | Tetra, Sia | Jauns XII faktora inhibitors |
| RU2458054C1 (ru) * | 2011-05-31 | 2012-08-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью |
| RU2457202C1 (ru) * | 2011-05-31 | 2012-07-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний)пропионата - 5- гидрокисиникотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью |
| RU2465268C1 (ru) * | 2011-08-08 | 2012-10-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Производное 3-(2,2,2-триметилгидразиний)пропионата - никотинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее эндотелиопротекторной активностью |
| LV14848B (lv) * | 2012-10-25 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Farmaceitiska kompozīcija trimetilamīna-N-oksīda līmeņa pazemināšanai |
| JO3117B1 (ar) * | 2012-12-20 | 2017-09-20 | Grindeks Jsc | استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين |
| LV14963B (lv) | 2013-06-28 | 2015-10-20 | Tetra, Sia | Endoteliālās disfunkcijas korektors |
| GB201413355D0 (en) * | 2014-07-28 | 2014-09-10 | Innospec Ltd | Compositons and methods |
| CN104997754A (zh) * | 2015-08-05 | 2015-10-28 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种解热镇痛药阿司匹林组合物胶囊 |
| CN105106134A (zh) * | 2015-09-23 | 2015-12-02 | 青岛华之草医药科技有限公司 | 一种解热镇痛抗炎药阿司匹林组合物颗粒剂 |
| CN106008257A (zh) * | 2016-03-16 | 2016-10-12 | 江苏悦兴药业有限公司 | 米屈肼的制备方法及其关键中间体 |
| WO2018222583A1 (en) | 2017-05-30 | 2018-12-06 | Rho Pharmaceuticals, Llc | In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin) |
| RU2694835C1 (ru) * | 2018-12-07 | 2019-07-17 | Федеральное государственное автономное образовательное учреждение высшего образования "Северный (Арктический) федеральный университет имени М.В. Ломоносова" | Средство, повышающее резистентность организма в постгипотермическом периоде |
| JP2024511323A (ja) * | 2021-03-08 | 2024-03-13 | エルジー ハウスホールド アンド ヘルスケア リミテッド | カルニチンサリシレートを有効成分として含む化粧料組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19839443A1 (de) * | 1998-08-29 | 2000-03-02 | Miklos Ghyczy | Arnzneimittel mit entzündungshemmender Wirkung |
| WO2006128600A2 (de) * | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler wirkstoffkomplex von salzen der o-acetylsalicylsäure mit basischen aminosäuren und glycin |
| WO2007021164A1 (en) * | 2005-08-15 | 2007-02-22 | Latvian Institue Of Organic Synthesis | Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3312593A (en) | 1965-03-10 | 1967-04-04 | Carter Prod Inc | Anti-inflammatory compositions of aspirin and niacin |
| JPS5610110A (en) * | 1979-07-06 | 1981-02-02 | Green Cross Corp:The | Acetyl salicylate salt preparation for injection |
| FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US4625888A (en) | 1985-11-18 | 1986-12-02 | Thompson Andy L | Ground actuated lid operating system |
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| CH679856A5 (enExample) * | 1990-07-04 | 1992-04-30 | Lonza Ag | |
| US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| WO1996032942A1 (en) | 1995-04-19 | 1996-10-24 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
| FR2744918B1 (fr) | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| FR2751540B1 (fr) | 1996-07-26 | 1998-10-16 | Sanofi Sa | Composition pharmaceutique antithrombotique |
| US6469035B1 (en) | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
| US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
| DE10034802A1 (de) * | 2000-07-18 | 2002-01-31 | Bayer Ag | Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren |
| DE10202019A1 (de) * | 2002-01-18 | 2003-07-24 | Bayer Ag | Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II |
| DK1667960T3 (da) * | 2003-08-04 | 2008-06-09 | Grindeks Jsc | Meldoniumsalte, fremgangsmåde til deres fremstilling og farmaceutisk sammensætning på deres basis |
| JP2008533044A (ja) | 2005-03-11 | 2008-08-21 | ホン コン ナイトリック オキサイド リミテッド | 内皮機能不全、アンギナおよび糖尿病のための組合せ治療 |
| ITMI20052459A1 (it) * | 2005-12-22 | 2007-06-23 | Isagro Spa | Sali quaternari e relativo uso per il controllo di fitopatogeni |
| RU2010151944A (ru) | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
-
2010
- 2010-06-21 BR BRPI1009600A patent/BRPI1009600A2/pt not_active IP Right Cessation
- 2010-06-21 US US13/377,926 patent/US8889902B2/en active Active
- 2010-06-21 WO PCT/LV2010/000007 patent/WO2010151095A1/en not_active Ceased
- 2010-06-21 EP EP10735094.4A patent/EP2445861B1/en active Active
- 2010-06-21 KR KR1020127001929A patent/KR20120050437A/ko not_active Ceased
- 2010-06-21 CN CN201080028833.9A patent/CN102803199B/zh not_active Expired - Fee Related
- 2010-06-21 GE GEAP201012546A patent/GEP20146015B/en unknown
- 2010-06-21 NZ NZ597510A patent/NZ597510A/xx not_active IP Right Cessation
- 2010-06-21 JP JP2012517421A patent/JP5706409B2/ja not_active Expired - Fee Related
- 2010-06-21 CA CA2766048A patent/CA2766048A1/en not_active Abandoned
- 2010-06-21 EA EA201200038A patent/EA021588B1/ru not_active IP Right Cessation
-
2011
- 2011-12-15 IL IL217036A patent/IL217036A/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19839443A1 (de) * | 1998-08-29 | 2000-03-02 | Miklos Ghyczy | Arnzneimittel mit entzündungshemmender Wirkung |
| WO2006128600A2 (de) * | 2005-06-02 | 2006-12-07 | Bayer Healthcare Ag | Stabiler wirkstoffkomplex von salzen der o-acetylsalicylsäure mit basischen aminosäuren und glycin |
| WO2007021164A1 (en) * | 2005-08-15 | 2007-02-22 | Latvian Institue Of Organic Synthesis | Pharmaceutical composition on basis of reverse transcriptase inhibitor and meldonium |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010151095A8 (en) | 2012-05-18 |
| EA201200038A1 (ru) | 2012-10-30 |
| US20120088742A1 (en) | 2012-04-12 |
| JP5706409B2 (ja) | 2015-04-22 |
| HK1169648A1 (en) | 2013-02-01 |
| IL217036A (en) | 2015-03-31 |
| EP2445861B1 (en) | 2014-03-26 |
| WO2010151095A1 (en) | 2010-12-29 |
| US8889902B2 (en) | 2014-11-18 |
| CA2766048A1 (en) | 2010-12-29 |
| JP2012531408A (ja) | 2012-12-10 |
| IL217036A0 (en) | 2012-02-29 |
| GEP20146015B (en) | 2014-01-27 |
| NZ597510A (en) | 2012-12-21 |
| KR20120050437A (ko) | 2012-05-18 |
| CN102803199B (zh) | 2015-04-15 |
| CN102803199A (zh) | 2012-11-28 |
| BRPI1009600A2 (enExample) | 2016-03-22 |
| EP2445861A1 (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA021588B1 (ru) | Бетаиновые соли ацетилсалициловой кислоты | |
| US7109364B2 (en) | Group of anti-cancer compounds with specific structure and their production method | |
| US4711903A (en) | Phenolic thioethers as inhibitors of 5-lipoxygenase | |
| CZ20004778A3 (en) | Farnesyl-protein transferase inhibitory employed for treating arthropaties | |
| Korkmaz-Icöz et al. | Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway | |
| US20070203212A1 (en) | Method of treating osteoarthritis | |
| WO2014170873A1 (en) | Compounds with a sirtuin inhibiting activity | |
| IE851821L (en) | Anticoagulant composition | |
| CA1330446C (en) | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | |
| EA030138B1 (ru) | Фармацевтические композиции, включающие антикоагулянт n-(5-хлорпиридин-2-ил)-2-({4-[этанимидоил(метил)амино]бензоил}амино)-5-метилбензамид | |
| JP2006501238A (ja) | 骨関節炎を治療する方法 | |
| CN113181160A (zh) | 异硫氰酸酯类化合物的用途 | |
| KR20190114299A (ko) | RhoA 억제제 및 이의 용도 | |
| US20190382336A1 (en) | HYPDH Inhibitors and Methods of Use for the Treatment of Kidney Stones | |
| AU2010263409B2 (en) | Novel acetylsalicylic acid salts | |
| US5162365A (en) | 5-lipoxygenase inhibitors | |
| Anderson et al. | Effect of NaCl and Desoxycorticosterone on Body Weight and Carbohydrate Stores of Adrenalectomized Rats. | |
| WO2014170875A1 (en) | Quinazolinedione componds with a sirtuin inhibiting activity | |
| Goncharova et al. | Model development of hydroxyproline induced hyperoxaluria in young growing pigs | |
| KR20090065575A (ko) | 항염증 작용을 하는 녹용내 글라이코사민-단백질 추출물 및그 분획물의 추출기법과 이를 이용한 약제 및 음료수 제조방법 | |
| LV14468B (lv) | Pretiekaisuma līdzeklis | |
| Lyons | THE FORMATION OF GLYCOGEN IN THE LIVER OF THE WHITE RAT FOLLOWING THE ADMINISTRATION OF CERTAIN SYNTHETIC ORGANIC ACIDS | |
| JPS646167B2 (enExample) | ||
| Kuppusamy et al. | Anti-secretory and Acid Neutralizing Effect of Shankha Draavaka in Albino Rats | |
| JPS60227630A (ja) | 食肉類の冷凍変性防止剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |